newsare.net
TOKYO -- More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said.Research team confirms safety of Alzheimer's drug Lecanemab
TOKYO -- More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said. Read more











